[Top][All Lists]

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Promo Movers: Weekly Member Newsletter

From: Chandra Casey
Subject: Promo Movers: Weekly Member Newsletter
Date: Fri, 07 May 2004 01:17:48 +0000

Gotham Financial Daily

BioElectronics Corp.



Check out the gains from recent strong-buy recommendations...

December?HTSC at .70        High 3.25....410% Gain!
January?...QLHC at  90        High 3.50....
389% Gain!
April ??.....IPYS at .30        High 1.10.....
266% in two days     

These types of gains happen every day in the world of Pink sheets!  Lets look at today's featured company: Bioelectronics Corp.

Bioelectronics Corp: BIEL 
Current-Price: $0.80 

Reasons to buy BIEL.PK : BIEL (Bioelectronics Corporation) is taking proven medical technologies and making them available to more people in new convenient, cost-effective dermal patches.  By applying advanced microelectronic technology, Bioelectronics is dramatically reducing the size and the cost of some well-establ

BIEL first FDA cleared product, ACTIPATCH (TM) therapy is a dermal patch with an embedded microchip that delivers weeks of continuous pulsed electromagnetic energy.  ActiPatch therapy is the miniaturized equivalent of the large pulsed electromagnetic energy machines prescribed by physicians for decades to reduce swelling, relieve pain and enhance the healing of surgical incisions, accidental wounds, sprains, strains and chronic wounds (bedsores).  ActiPatch's size, portability, ease of use and relatively low price overcomes the obstacles to use associated with the large, expensive, stationary machines.  The introduction of ActiPatch provides an immediate therapeutic alternative for the 200 million surgical and non-surgical soft tissue injuries across the U.S. annually.  BioElectronics has launched it's ActiPatch product line in cooperative distribution relationships with several well-established medical device companies in various medical market segments.

New Products and Additional Applications: BIEL and leading pharmaceutical and device manufacturers and conducting new clinical trials.  These trials include: Abdominoplasty -- pain; Face and Forehead Lifts -- pain and edema, Facial Fat Injections -- pain and edema; Heel -- pain and healing; Oral Surgery -- pain; Swelling and accelerated healing; and Abdominal Surgery -- pain and accelerated healing.  Successful results in these trials will be published and used to secure additional FDA approved indications of use. 

BIEL is developing products for the treatment of chronic pain, arthritis, inflammatory skin conditions, and chronic wounds.


Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will", "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. WE advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. GS Research and/or its officers and employees have been compensated $10,000.00 cash by a third party for work involved in the preparation and production of this report

In compliance with Section 17(b), we disclose the holding of independently purchased shares of the company mentioned prior to the publication of this report.. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. Short term trading targets are only guesses on our part. Keep in mind that when trading small stocks like the company above there is a chance you will lose every penny you invest. Furthermore there have been times in the past when the Company itself tells lies, gives false information and puts out false news. This email is for entertainment purposes only. This is not investment advice. We suggest you check with an investment professional before investing any stocks or mutual funds.


reply via email to

[Prev in Thread] Current Thread [Next in Thread]